Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Kristoff Muylle, P. Flamen, DJ Vugts, T Guiot, G Ghanem, N Meuleman, P Bourgeois, B Vanderlinden, GAMS van Dongen, Hendrik Everaert, M Vaes, D Bron

Onderzoeksoutput: Article

Originele taal-2English
Pagina's (van-tot)1304-1314
TijdschriftEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume42
StatusPublished - 2015

Citeer dit